Johnson & Johnson splits into two as big pharma downsizes
The company’s decision to split is likely being made so it can focus on its fast-growing pharmaceutical and medical device units.
By
MarketLine
Latest articles
All Articles
Covid-19 epidemic will reshape patient behaviour, accelerating digitalisation of healthcare system
The projected timeline for adopting digital medical services is becoming significantly shorter due to the impacts of Covid-19. Prior…
By
Pharmaceuticals contrasts travel and tourism following China’s coronavirus outbreak
Chinese drugmakers experience a 10% increase in share prices following a rising number of people infected by the coronavirus.…
By
Psilocybin moves closer to becoming a licensed treatment for depression
The main psychoactive component in magic mushrooms, psilocybin, has passed its first clinical safety trial. The drug is now…
By
Inclisiran drives Novartis to buy The Medicines Company
Drug maker Novartis could become a leader in CVD therapeutics after purchasing The Medicine Company and its Atherosclerotic cardiovascular…
By
Climate change means fresh opportunities for pharmaceutical companies
225 of the world’s largest corporations highlighted roughly $2.1 trillion of possible opportunities to capitalise on climate change, including…
By
The race to buy gene therapy developers is intensifying
Despite a small rally at the start of the year, the US biotech index still looks relatively cheap compared…
By
Trump administration proposal may neuter America’s tapeworm PBMs
The United States Department of Health and Human Services has proposed new limitations on pharmacy benefit manager rebates.
By
Why Sangamo’s shares tanked by 48%
The trial results raised concerns that the therapy will be unable to integrate enough corrective genetic material into the…
By